Sindrome.del.Ovario.Poliquistico

178 Síndrome del Ovario Poliquístico
of Clinical Endocrinology & Metabolism.
2004 Oct;90:66-71 (edición electrónica).
12
Teimuraz Apridonidze, Paulina A, Essah,
Maria J, Iurno, John E, et al. Prevalence
and characteristics of the Metabolic Syndrome
in women with polycystic ovary
syndrome. The Journal of Clinical Endocrinology
& Metabolism. 10.1210/jc.2004-
1045 (edición electrónica). 2004.
13
Escobar-Morreate H, Luque M, San
Millán JL. Síndrome metabólico y SOP
comparten genes. Endocrine Reviews on
line; 2004.
14
Sepilian V, Nagamani M. Effects of
Rosiglitazone in obese women with
polycystic ovary syndrome and severe
insulin resistance. The Journal of Clinical
Endocrinology & Metabolism. 2004
Oct;90:60-5 (edición electrónica).
15
Blumenfeld Z. Obesity, lipids, cardiovascular
risk, and androgen excess. Clin
Endocrinol Metab. 2004;89:2160-5.
16
Legro RS, Blanche P, Krauss RM, Lobo
RA. Alterations in low-density lipoprotein
and high-density lipoprotein subclasses
among Hispanic women with
polycystic ovary syndrome: influence of
insulin and genetic factors. Fertil Steril.
1999;72:990-5.
17
Wild RA. Obesity, lipids, cardiovascular
risk, and androgen excess. Am J Med.
1995;98(Suppl 1A):27S-32S.
18
Holte J, Bergh T, Berne C, Lithell H.
Serum lipoprotein lipid profile in women
with the plycystic ovary syndrome:
Relation to anthropometric, endocrine
and metabolic variables. Clin Endocrinol.
1994;41:463-71.
19
Documentos de Consenso S.E.G.O. Grupo
Síndromes Hiperandrogénicos; 1998.
p. 107-43.
20
Blumenfeld Z. Clin Endocrinol Metab.
2004;89:2160-5.
21
Dahlgren E, Johansson S, Lindstedt G,
Knutsson F. Women with polycystic
ovary syndrome wedge resected in 1956-
1965: a long-term follow-up focusing
on natural history and circulating hormones.
Fertil Steril. 1992;57:505-13.
22
Conway GS, Agrawal R, Betteridge
DJ, Jacobs HS. Risk factors for coronary
artery disease in lean and obese
women with the polycystic ovary syndrome.
Clin Endocrinol (Oxf). 1992;37:
119-25.
23
Talbott E, Guzick D, Clerici A, Berga
S, Detre K, Weimer K, et al. Coronary
heart disease risk factors in women with
polycystic ovary syndrome. Arterioscler
Thromb Vasc Biol. 1995;15:821-6.
24
Birdsall MA, Farquahar CM, White HD.
Association between polycystic ovaries
and extent of coronary disease in young
women having cardiac catheterization.
Ann Intern Med. 1997;126:32-5.
25
Dahlgren E, Janson PO, Johansson S,
Lapidus L, Oden A. Polycystic ovary
syndrome and risk for miocardial infarction.
Evaluated from a risk factor model
based on prospective population study
of women. Acta Obstet Gynecol Scand.
1992;71:599-603.
26
DiSaia P, Creasman W. Endometrial
Hyperplasia/Estrogen Therapy. Adenocarcinoma
of the Uterus. In: Clinical
Gynecologic Oncology. St. Louis Mo:
Mosby; 1997. p. 108-67.
27
Carmina E, Lobo RA. Polycystic ovary
syndrome (PCOS): arguably the most
common endocrinopathy is associated
with significant morbidity in women.
J Clin Endocrinol Metab. 1999;84:
1897-9.
28
Schildkraut JM, Schwingl PJ, Bastos E,
Evanoff A, Hughes C. Epithelial ovarian
cancer risk among women with polycystic
ovary syndrome. Obstet Gynecol.
1996;88:554-9.
29
Cuello MC, Brañes JA. Bases moleculares
en el diseño de nuevas terapias
en cáncer ginecológico. Rev Chil Obstet
Ginecol. 2001;66(2):138-53.
30
Sandberg T, Ehinger A. Paracrine
stimulation of capillary endotheliall
cell migration by endometrial tissue
invovles epidemal growth factor and